GlassScriptPhysician profile
Tricia J Brown
NPI 1538151865
$23,823.41
in general payments reported to CMS, 2019-2025
39 companies · $3,302 in 2025
The $3,302 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,780 · 2020: $2,399 · 2021: $4,869 · 2022: $2,853 · 2023: $2,740 · 2024: $3,880 · 2025: $3,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,540 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $224 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,539.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $224.45 |
| Education | $158.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,115.01 | 2019-2023 | |
| Abbvie INC. | $2,100.50 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Almirall LLC | $1,858.08 | 2019-2025 | Klisyri, Seysara |
| Allergan, INC. | $1,799.10 | 2019-2023 | |
| Lilly USA, LLC | $1,640.80 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $1,561.91 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $1,535.21 | 2019-2025 | |
| Incyte Corporation | $1,215.06 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $977.00 | 2019-2025 | Dysport, Aklief, Nemluvio |
| Ucb, INC. | $943.65 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $862.08 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $840.92 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $822.07 | 2019-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $625.44 | 2019-2025 | Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $587.32 | 2022-2025 | Sotyktu |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $579.37 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Genzyme Corporation | $525.28 | 2019-2025 | |
| Pfizer INC. | $497.71 | 2019-2024 | |
| Dermavant Sciences, INC. | $432.25 | 2022-2024 | Vtama |
| Leo Pharma INC. | $420.23 | 2019-2025 | Adbry, Anzupgo |
| Revance Therapeutics, INC. | $229.92 | 2024 | Daxxify |
| Arcutis Biotherapeutics, INC. | $196.52 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $162.17 | 2020-2021 | |
| Celgene Corporation | $161.08 | 2019 | |
| Epi Health, LLC | $150.27 | 2020-2022 | |
| Dermira, INC. | $142.86 | 2019-2020 | |
| Strata Skin Sciences, INC. | $120.05 | 2019-2024 | Xtrac |
| Sanofi-Aventis U.S. LLC | $116.70 | 2019-2024 | |
| Organon LLC | $109.82 | 2025 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $98.93 | 2019-2025 | Neo-Synalar |
| Botanix Sb INC | $85.16 | 2025 | Sofdra |
| Journey Medical Corporation | $71.44 | 2020-2025 | |
| Verrica Pharmaceuticals INC. | $60.94 | 2024 | Ycanth |
| Mission Pharmacal Company | $39.98 | 2020-2021 | |
| Biofrontera INC. | $36.56 | 2019 | |
| Organogenesis INC. | $31.99 | 2024 | |
| Aclaris Therapeutics, INC. | $31.01 | 2019 | |
| Sandoz INC. | $19.94 | 2019 | |
| Fidia Pharma USA INC. | $19.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tricia Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.